

Subgrouping the autism "spectrum": reflections on DSM-5

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

open access

Lai, M.-C., Lombardo, M. V., Chakrabarti, B. and Baron-Cohen, S. (2013) Subgrouping the autism "spectrum": reflections on DSM-5. PLoS Biology, 11 (4). e1001544. ISSN 1544-9173 doi: <https://doi.org/10.1371/journal.pbio.1001544> Available at <http://centaur.reading.ac.uk/32453/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

Published version at: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001544>

To link to this article DOI: <http://dx.doi.org/10.1371/journal.pbio.1001544>

Publisher: Public Library of Science

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online



Perspective

Subgrouping the Autism “Spectrum”: Reflections on DSM-5

Meng-Chuan Lai^{1,2*}, Michael V. Lombardo¹, Bhisudev Chakrabarti^{1,3}, Simon Baron-Cohen¹

1 Autism Research Centre, Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom, **2** Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan, **3** School of Psychology and Clinical Language Sciences, Centre for Integrative Neuroscience and Neurodynamics, University of Reading, Reading, United Kingdom

The biology of autism cannot yet be used diagnostically, and so—like most psychiatric conditions—autism is defined by behavior [Rett syndrome (Rett’s disorder) is diagnosed by incorporating biology, but it has been moved out of the “Autism Spectrum Disorder” category in DSM-5]. The two international psychiatric classification systems (the Diagnostic and Statistical Manual of Mental Disorders [DSM] and the International Classification of Diseases [ICD]) remain useful for making clinical diagnoses, but each time these classification systems are revised, the new definitions inevitably subtly change the nature of how the conditions are construed. While acknowledging concerns about issues such as diagnostic inflation [1] and financial conflicts of interest [2], DSM-5 is now “set in stone” and will be published in May 2013. Although this manual is primarily designed for creating a common language for clinical practice, it is also often used in research settings to define the conditions to be studied. Here we reflect on what the revision may mean for research, and for understanding the nature of autism.

New in DSM-5 is the explicit recognition of the “spectrum” nature of autism, subsuming and replacing the DSM-IV Pervasive Developmental Disorder (PDD) categorical subgroups of “autistic disorder,” “Asperger’s disorder,” “pervasive developmental disorder not otherwise specified,” and “childhood disintegrative disorder” into a single umbrella term “Autism Spectrum Disorder” (ASD). [Here and throughout we use the term “ASD” because this is what is used in DSM-5. However, in our publications over many years we have opted for the more neutral term “ASC” (Autism Spectrum Conditions) to signal that this is a

biomedical diagnosis in which the individual needs support, and which leaves room for areas of strength as well as difficulty, without the somewhat negative overtones of the term “disorder,” which implies something is “broken.”] DSM-5 characterizes ASD in two behavioral domains (difficulties in social communication and social interaction, and unusually restricted, repetitive behaviors and interests) and is accompanied by a severity scale to capture the “spectrum” nature of ASD.

Also new in DSM-5, language development/level is treated as separate from ASD. This means an individual can have ASD *with* or *without* a language disorder. Finally, DSM-5 proposes a more inclusive age-of-onset criterion, recognizing that although symptoms should present in early childhood, they may not fully manifest until social demands exceed the capacity of the individual to cope with them. The major rationale behind these changes is to improve reliability [3]. The DSM-5 field trial in North America has shown that ASD diagnosis has reasonable test-retest

reliability, with an intraclass Kappa (a statistical measure of reliability) of 0.69 (95% CI 0.58–0.79) [4].

There have been concerns that the DSM-5 criteria may be more stringent than DSM-IV, such that some individuals who qualified for PDD will not meet the new ASD criteria. A series of studies testing the initial [5] and revised draft ASD criteria [6–12] showed increased specificity but decreased sensitivity of the DSM-5 draft compared to DSM-IV, and suggested relaxation of the threshold (e.g., fewer numbers of required symptom subdomains) to achieve reasonable sensitivity. However, most of these studies suffer from the weakness of using retrospective datasets and tools developed earlier that may not satisfactorily capture symptoms now included in DSM-5 [13]. One prospective study tested both DSM-IV and DSM-5 criteria against the gold standard of “best-estimate clinical diagnoses” and agreed with the “too-stringent” conclusion in a clinical sample [14]. However, another substantially large ret-

Citation: Lai M-C, Lombardo MV, Chakrabarti B, Baron-Cohen S (2013) Subgrouping the Autism “Spectrum”: Reflections on DSM-5. *PLoS Biol* 11(4): e1001544. doi:10.1371/journal.pbio.1001544

Academic Editor: Eric Nestler, Mount Sinai School of Medicine, United States of America

Published: April 23, 2013

Copyright: © 2013 Lai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Meng-Chuan Lai is supported by the Waterloo Foundation (<http://www.waterloofoundation.org.uk/index.html>), Wolfson College, Cambridge (<http://www.wolfson.cam.ac.uk/>), and the European Autism Interventions – A Multicentre Study for Developing New Medications (EU-AIMS, <http://www.eu-aims.eu/>); the research of EU-AIMS receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115300, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013), from the EFPIA companies in kind contribution and from Autism Speaks). Michael V. Lombardo is supported by the British Academy (<http://www.britac.ac.uk/>) and Jesus College, Cambridge (<http://www.jesus.cam.ac.uk/>). Bhisudev Chakrabarti is supported by the Medical Research Council, UK (<http://www.mrc.ac.uk/index.htm>). Simon Baron-Cohen is supported by the Wellcome Trust (<http://www.wellcome.ac.uk/>) and the Medical Research Council, UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Abbreviations: AQ, Autism Spectrum Quotient; ASC, Autism Spectrum Conditions; ASD, Autism Spectrum Disorder; ASSQ, Autism Spectrum Screening Questionnaire; BAP, broader autism phenotype; CAST, Childhood Autism Spectrum Test; DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International Classification of Diseases; NIMH, US National Institute of Mental Health; PDD, Pervasive Developmental Disorder; Q-CHAT, Quantitative Checklist for Autism in Toddlers; SRS, Social Responsiveness Scale.

* E-mail: mcl45@cam.ac.uk

The Perspective section provides experts with a forum to comment on topical or controversial issues of broad interest.

rospective study using data from three existing datasets found few differences between the two systems in sensitivity [15].

In brief, these studies all show that DSM-5 provides better specificity (so reducing false-positive diagnoses), but at the expense of potentially reduced sensitivity, especially for older children, adolescents and adults, individuals without intellectual disability, and individuals who previously met criteria for diagnoses of DSM-IV “Asperger’s disorder” or “pervasive developmental disorder not otherwise specified.” It remains to be seen in real-life settings how diagnostic practice, service delivery, and prevalence estimates will be affected by applying DSM-5 ASD criteria. In particular, one major nosological issue is to what extent individuals fitting DSM-IV PDD but not DSM-5 ASD diagnoses will end up falling into the newly created diagnosis of “Social (Pragmatic) Communication Disorder” [12,16–18]. Clearly more research needs to be done to provide a thorough and fair evaluation of this revision.

Highlighting the dimensional nature of the two cardinal behavioral domains of ASD, as well as the improved organization of symptom descriptions, are excellent features of DSM-5. A unitary label of “ASD” accompanied by individualized assessment of needs for support will likely be useful in clinical settings, especially to guarantee the required levels of support for all individuals “on the spectrum” who will benefit from educational, occupational, social, mental health, and medical interventions (even if they are etiologically, developmentally, and clinically heterogeneous). However, this approach is not useful for research in general, given the known massive heterogeneity within such an omnibus label. Within autism there is a huge variability in terms of behavior (symptom severity and combination), cognition (the range of deficits and assets), and biological mechanisms. Acknowledging heterogeneity has led to the idea that there are many “autisms,” with partially distinct etiologies, nested within the umbrella term of “ASD” [19]. Therefore, two critical issues need to be addressed: a clarification of the meaning(s) of the term “spectrum”; and the need for subgrouping.

What Do We Mean by the Autism “Spectrum”?

There are several meanings of the term “spectrum” in relation to autism. The differences are subtle but nontrivial. DSM-5 does not tease these apart, but in relation

to future research into the “autism spectrum,” it is important to be clear to which meaning the term “spectrum” refers.

1. “Spectrum” can refer to the dimensional nature of the cardinal features of autism *within the clinical population* (i.e., differences in the severity and presentation of symptoms among those with a diagnosis of ASD). This was suggested in the 1970s, before autism appeared in DSM-III, when Lorna Wing highlighted the diversity among the cardinal behavioral domains within autism [20].
2. “Spectrum” can also refer to the *continuity between the general population and the clinical population*. This view of the spectrum requires the concept of “autistic traits” (sometimes referred to as “autistic-like traits”) that run right through the whole population. Autistic traits can refer to the individual features that together comprise the quantitative variability in the *cardinal* behavioral domains defined by DSM/ICD criteria. Studies using questionnaire measures of autistic traits (e.g., the Quantitative Checklist for Autism in Toddlers [Q-CHAT] [21], the Childhood Autism Spectrum Test [CAST] [22], and the Autism Spectrum Screening Questionnaire [ASSQ] [23]) show a continuous distribution of scores, supporting the concept of a spectrum extending into the general population. Underlying autistic traits are genetic susceptibilities that are common across the general population and at the extreme ends [24], and for clinically defined ASD [25]. “Autistic traits” can also refer to *associated features* not described in DSM/ICD criteria, exemplified by items within questionnaires such as the Social Responsiveness Scale (SRS) [26] (e.g., “Becomes upset in a situation with lots of things going on”) or the Autism Spectrum Quotient (AQ) [27] (e.g., “I tend to notice details that others do not”). These composite measures of autistic traits (including *both* cardinal and associated features) are also continuously (and normally) distributed, and have been used to characterize the “broader autism phenotype” (BAP) [28,29]. These traits also show shared genetic association with clinically defined ASD [30].
3. “Spectrum” can also refer to *subgroups* [31,32]. It has been suggested that “the autisms” may be a useful concept to reflect the substantial heterogeneity within the autistic spectrum [19]. DSM-5 has tried to move away from

subgrouping “to stop trying to ‘carve meatloaf at the joints’ and instead recognize the essential shared features of the autism spectrum while attempting to individualize diagnosis through dimensional descriptors” (p. 541) [32]. While it is likely that the reliability of diagnosis will improve by using the broader ASD label (compared to using DSM-IV subtypes), to understand the biology of “the autisms,” it is necessary to clarify not just the similarities but also the differences among subgroups.

Subgrouping and the Use of “Specifiers”

DSM-5 holds back from listing subgroups by recommending the use of “specifiers” to record the severity of cardinal symptoms, current language and intellectual ability, onset age and pattern, and concurrent genetic/medical or environmental/acquired conditions [33]. The use of specifiers is likely to be a valuable addition. However, there is a need to grasp the nettle to provide a more fine-grained taxonomy for research and clinical purposes (e.g., for access to appropriate individualized services). We therefore suggest expanding the list of specifiers toward the identification of clear subgroups. Table 1 summarizes our preliminary expanded but nonexhaustive list of specifiers, discussed here:

- a. *Developmental pattern*: Age and pattern of onset of atypical development should be recorded. This includes not only “regression” [34] but also language onset/development and atypical social, emotional, communicative, physical and general intellectual development. These developmental patterns may have etiological implications. Differences in the trajectories of changes in autistic features [35,36] may also have etiological implications, and are relevant to clinical management and prognosis. Development of prognostic biomarkers (e.g., of language outcome) may be particularly useful.
- b. *Sex/gender*: There are substantial sex/gender-specific effects at a variety of levels (e.g., behavior and cognition [37,38], genetics [39,40], proteomics [41], and neuroanatomy [42,43]), which contribute to heterogeneity. For this reason, sex/gender should not just be viewed as a demographic descriptor but also an important specifier toward subgrouping “the

autisms.” In the general population there is a sex/gender difference in the distribution of autistic traits [26,44]. If we view autism as the extreme of a continuous distribution of autistic traits in the population, one important specifier could be a statistical measure of where an individual lies on a sex/gender-specific distribution (e.g., percentile or z-score). Any statistical characterization would require sex/gender-specific norms and thresholds for defining ASD. There are many precedents for sex/gender-specific statistical characterization in other fields of medicine. For example, “failure to thrive” is defined using sex-specific growth curves for infants, and anemia is defined using sex-specific norms of serum hemoglobin levels [45]. Currently, DSM-5 is sex/gender-blind: it uses identical diagnostic criteria for ASD for both males and females. Although it remains an open question whether sex/gender-specific norms, thresholds, or criteria should be adopted, we underscore the importance of sex/gender to aid future research into subgrouping, which may lead to the identification of important sex/gender-linked mechanisms [46]. This issue is especially relevant for understanding the male bias in prevalence and potential underrecognition of females [37,44,47].

c. *Clinical phenotypes*: DSM-5 recognizes concurrent medical and neuropsychiatric conditions, which of course is vital as a substantial portion of individuals with ASD show comorbidity. In addition to these, we suggest ASD could also be specified by other *prototypical* clinical subgroups, such as *Asperger syndrome* (e.g., defined by Hans Asperger’s initial report or the Gillberg criteria [48]) or Wing’s categorization (of the “aloof,” “passive,” “active but odd,” and “loners” groups) [49]. This would allow for more systematic investigation of these long-standing rich clinical descriptions, which have not been studied thoroughly yet. It is of particular concern that Asperger syndrome is not specified by DSM-5 given insufficient research being conducted into how this may differ from other forms of autism [50]. In the context of a relative lack of consensus in definition [51], research findings of similarities and differences between “Asperger syndrome” and so-called “high-functioning autism (autistic disorder)” can

either be interpreted as not supporting such a distinction [52] or that it is premature to rule out the separateness of the two [53]. Providing that the definition of the diagnosis adopted in the study is well described, in research using large samples it should be straightforward to identify a reliable signal, and the concern of unsatisfactory interrater reliability [32] may be alleviated.

d. *Cognitive profile*: Cognition plays a pivotal role linking brain and behavior in ASD [54], yet curiously remains absent in DSM-5. Cognitive specifiers would be relevant for research into subgrouping, for discovering biomarkers, and for clinical evaluation. While the variability of intelligence and structural properties of language (as well as their development) has long been acknowledged, and is predictive of prognosis [55,56], other aspects of cognition in autism may also be useful. Examples include *social cognition* (e.g., mentalizing/theory of mind, emotion processing, social orienting and reward processing), *executive function* (e.g., cognitive flexibility, planning, inhibitory control, attention shifting), *bottom-up perceptual processing* (e.g., global-local perceptual processing, low-level perceptual function and discrimination), and *top-down information processing* (e.g., “central coherence,” “systemizing”—the drive to analyze and construct rule-based systems). Although some of the measures for these cognitive domains still lack general population norms, this should not prevent researchers and clinicians from including a systematic cognitive assessment focusing on these domains, for both research into individual differences and for individualized service planning.

e. *Known genetic correlates*: These have the potential to dissect “the autisms” into subgroups at the genetic level [57], so they are vital to record in both research and clinical settings [58]. This includes identifiable ASD-related genetic syndromes, chromosomal anomalies, and rare and highly penetrant *de novo* and non-*de novo* genetic variations (copy number variations and rare genetic variants) [57,59–61]. Depending on the pattern of familial aggregation and the nature of genetic variation (*de novo* vs. non-*de novo*), autism may be further classified into “simplex” and “multiplex.” In addition, common inherited variations (i.e., polymorphisms) and

de novo genetic variation of low penetrance in multiple genes in critical biochemical and cellular pathways associated with neurodevelopment [62] may underlie the autistic spectrum that extends on to the general population. Some of the candidate genes are listed in Table 1, but we refer the readers to <https://gene.sfari.org/autdb/Welcome.do> for a constantly updating database.

f. *Potential environmental contributors*: Perhaps due to the frequently reported high heritability of autism [63], environmental factors and gene-environment interplay in autism are understudied [64] but may also help toward identification of subgroups. For example, social deprivation early in life [65] or other environmental risk factor exposure (e.g., teratogens) and the timing of exposure [66] could be relevant and should be specified.

It is notable that the US National Institute of Mental Health (NIMH) has initiated the Research Domain Criteria [67] (with many of the above domains covered) to provide a system independent of DSM and ICD. Such initiatives are important to move toward identification of subgroups in a research context and for how they cut across DSM/ICD diagnostic categories. Such a system could provide a basis for identifying biological mechanisms that may or may not respect the DSM/ICD classification boundaries.

Conclusions

DSM-5 ASD criteria should be commended for its clearer symptom descriptions and grouping, for acknowledging the spectrum nature of autism, and for recognizing the dynamic nature of development and how individuals interact with their environment. Moreover, for clinical purposes a unitary label of ASD may be beneficial in planning the support systems for *all* individuals “on the spectrum” who require help from education and health- and social-care systems. However, it is important to remember that autism is not homogenous, and defining it using the umbrella term ASD risks whitewashing the evident heterogeneity, which has a substantial impact for research into this condition. The identification of core features of autism using the broader ASD label cannot overcome the existence of heterogeneity. It has simply moved us from the level of subgroups (“apples and oranges”) to the prototypical level (“fruit”). We argue that to make progress

Table 1. A preliminary expanded (but nonexhaustive) list of specifiers, toward the identification of subgroups.

Category	Specifier	Example
<i>Developmental pattern</i>	Pattern of atypical development	1. Age and pattern of onset/regression
		2. Trajectory of development
		3. Language onset
		4. Hyperlexia
<i>Sex/gender</i>	Biological sex	Male/female
	Sex/gender-adjusted autistic features	Statistical characterization of autistic trait (e.g., percentile) relative to sex/gender-specific norms
<i>Clinical phenotype</i>	Co-occurring condition	1. Epilepsy
		2. Macrocephaly
		3. Gastrointestinal disorders
		4. Immune disorders
		5. Hyperserotonemia
		6. Attention deficit/hyperactivity disorder
		7. Anxiety disorders
		8. Depressive disorders
		9. Tics/Gilles de la Tourette syndrome
		10. Obsessive-compulsive disorder
		11. Schizophrenia spectrum
		12. Dyslexia
		13. Personality disorders
		14. Self-injurious behaviors
		15. Sleep disruption
		16. Eating disorders
		17. Gender dysphoria
<i>Clinical phenotype</i>	Taxonomic formulation	1. Asperger syndrome 2. "Aloof"/"passive"/"active but odd"/"loners" groups
	Motor abnormality	1. Types of motor stereotypy 2. Coordination disorder 3. Dyspraxia
<i>Cognitive profile</i>	Intelligence	1. IQ profile (including discrepancy among subtests)
		2. Savant memory
		3. Savant spatial skills
	Current language (structural properties)	1. Phonological/phonetic processing (including articulation)
		2. Prosodic processing
		3. Morphological processing
		4. Syntactic processing
		5. Semantic processing
	Social cognition	6. Receptive vs. expressive abilities
		1. Emotion perception and understanding
		2. Face recognition
3. Emotional contagion		
4. Social orienting		
5. Social and nonsocial reward processing		
6. Affective empathy		
7. Sympathy		
8. Joint attention		
<i>Cognitive profile</i>		9. Pretend play
		10. Theory of mind/mental perspective taking
		11. Self-referential cognition
		12. Alexithymia

Table 1. Cont.

Category	Specifier	Example
		13. Metacognitive awareness
	Executive function	1. Cognitive flexibility 2. Planning 3. Inhibitory control 4. Attention shifting 5. Working memory 6. Time perception
	Bottom-up perceptual processing	1. Global-local perceptual processing 2. Low-level perceptual function and discrimination 3. Synesthesia
	Top-down information processing	1. "Central coherence" (global-local contextual processing) 2. "Systemizing" (drive to construct rule-based systems, ability to understand rule-based systems, knowledge of factual systems)
Genetics	Syndromic autism	1. Fragile X syndrome 2. Rett syndrome 3. Tuberous sclerosis complex 4. Timothy syndrome 5. Down syndrome 6. Phenylketonuria 7. CHARGE syndrome 8. Angelman syndrome 9. PTEN macrocephaly syndrome 10. Joubert syndrome 11. Landau-Kleffner syndrome 12. Prader-Willi syndrome 13. Smith-Lemli-Opitz syndrome 14. Neurofibromatosis
	Familial aggregation	Simplex vs. multiplex
	Gene-level variations	e.g., <i>ASTN2</i> , <i>AVPR1A</i> , <i>CACNA1C</i> , <i>CACNA1G</i> , <i>CDH8</i> , <i>CDH9</i> , <i>CDH10</i> , <i>CNTN4</i> , <i>CNTNAP2</i> , <i>DISC1</i> , <i>DPP6</i> , <i>DPYD</i> , <i>EN2</i> (<i>Engrailed 2</i>), <i>FMR1</i> , <i>FOXP2</i> , <i>GABRA4</i> , <i>GABRB3</i> , <i>GluR6</i> , <i>GRIK2</i> , <i>GSTP1</i> , <i>HOXA1</i> , <i>HOXB1</i> , <i>ITGB3</i> , <i>MACROD2</i> , <i>MADCAM1</i> , <i>MAPK3</i> , <i>MBDS</i> , <i>MECP2</i> , <i>MET</i> , <i>NLGN3</i> , <i>NLGN4X</i> , <i>NRXN1</i> , <i>NRXN3</i> , <i>OXTR</i> , <i>PRKCB1</i> , <i>PRL</i> , <i>PRLR</i> , <i>PTCHD1/PTCHD1AS</i> , <i>PTEN</i> , <i>RELN</i> (<i>Reelin</i>), <i>SEMA5A</i> , <i>SERT</i> (<i>SLC6A4</i>), <i>SHANK1</i> , <i>SHANK2</i> , <i>SHANK3</i> (<i>ProSAP2</i>), <i>SLC25A12</i> , <i>TSC1</i> , <i>TSC2</i> , <i>UBE3A</i>
	Copy number variations (CNVs)	(specify known ASD-association status, genetic loci, and deletion/duplication)
Environmental risks	Social deprivation	Early social isolation or neglect* *(specify timing: postnatal months X to Y)
	Environmental risk factor exposure	1. Rubella virus infection during gestation* 2. Valproic acid exposure during gestation* 3. Antidepressant exposure during gestation* *(specify timing: gestational weeks X to Y)

doi:10.1371/journal.pbio.1001544.t001

in autism research, and ultimately to improve clinical practice, we need to move forward in the identification of subgroups within the autism spectrum.

Toward this end, we have expanded the list of possible dimensional and categorical "specifiers" to improve our recognition of "the autisms." In addition, it is important to clarify the different definitions of the term "spectrum." Given that the spectrum

extends into the general population, research needs to address the relationship between cardinal autistic symptoms and associated autistic traits (such as excellent attention to detail). Finally, we need to be fully aware of the inherent limitations of the existing psychiatric diagnostic systems, and consider other approaches that may be beneficial for research purposes [68].

The practical implication of the arguments proposed in this article is that *parallel behavioral characterization systems* may be necessary for autism research from now on. Although DSM-5-based diagnoses are expected to be widely accepted by researchers, a list of specifiers (including and beyond those recommended here) to aid phenotypic characterization will prevent us from losing sight of "the autisms." In a

world that is moving toward individualized medicine, not incorporating information about such specifiers will be a backward step. Last but not least, in

order to provide the basis to compare with the rich studies to date and to accurately assess the impact of shifting from DSM-IV to DSM-5, a parallel

record of DSM-IV diagnoses may be helpful for both research and clinical settings in which these issues are particularly of concern.

References

1. Frances A (2012) DSM-5 is a guide, not a bible: simply ignore its 10 worst changes. *Huffington Post Science*.
2. Cosgrove L, Krinsky S (2012) A comparison of DSM-IV and DSM-5 panel members' financial associations with industry: a pernicious problem persists. *PLoS Med* 9: e1001190. doi:10.1371/journal.pmed.1001190
3. Lord C, Jones RM (2012) Annual research review: re-thinking the classification of autism spectrum disorders. *J Child Psychol Psychiatry* 53: 490–509.
4. Regier DA, Narrow WE, Clarke DE, Kraemer HC, Kuramoto SJ, et al. (2013) DSM-5 field trials in the United States and Canada, part II: test-retest reliability of selected categorical diagnoses. *Am J Psychiatry* 170: 59–70.
5. Mattila ML, Kielinen M, Linna SL, Jussila K, Ebeling H, et al. (2011) Autism spectrum disorders according to DSM-IV-TR and comparison with DSM-5 draft criteria: an epidemiological study. *J Am Acad Child Adolesc Psychiatry* 50: 583–592 e511.
6. Frazier TW, Youngstrom EA, Speer L, Embacher R, Law P, et al. (2012) Validation of proposed DSM-5 criteria for autism spectrum disorder. *J Am Acad Child Adolesc Psychiatry* 51: 28–40 e23.
7. McPartland JC, Reichow B, Volkmar FR (2012) Sensitivity and specificity of proposed DSM-5 diagnostic criteria for autism spectrum disorder. *J Am Acad Child Adolesc Psychiatry* 51: 368–383.
8. Matson JL, Kozlowski AM, Hattier MA, Horovitz M, Sipes M (2012) DSM-IV vs DSM-5 diagnostic criteria for toddlers with autism. *Dev Neurorehabil* 15: 185–190.
9. Matson JL, Hattier MA, Williams LW (2012) How does relaxing the algorithm for autism affect DSM-V prevalence rates? *J Autism Dev Disord* 42: 1549–1556.
10. Taheri A, Perry A (2012) Exploring the proposed DSM-5 criteria in a clinical sample. *J Autism Dev Disord* 42: 1810–1817.
11. Mayes SD, Black A, Tierney CD (2013) DSM-5 under-identifies PDDNOS: diagnostic agreement between the DSM-5, DSM-IV, and Checklist for Autism Spectrum Disorder. *Res Autism Spectr Disord* 7: 298–306.
12. Wilson CE, Gillan N, Spain D, Robertson D, Roberts G, et al. (2013) Comparison of ICD-10R, DSM-IV-TR and DSM-5 in an adult autism spectrum disorder diagnostic clinic. *J Autism Dev Disord*. In press.
13. Swedo SE, Baird G, Cook EH Jr, Happe FG, Harris JC, et al. (2012) Commentary from the DSM-5 Workgroup on Neurodevelopmental Disorders. *J Am Acad Child Adolesc Psychiatry* 51: 347–349.
14. Gibbs V, Aldridge F, Chandler F, Witzlsperger E, Smith K (2012) Brief report: an exploratory study comparing diagnostic outcomes for autism spectrum disorders under DSM-IV-TR with the proposed DSM-5 revision. *J Autism Dev Disord* 42: 1750–1756.
15. Huerta M, Bishop SL, Duncan A, Hus V, Lord C (2012) Application of DSM-5 criteria for autism spectrum disorder to three samples of children with DSM-IV diagnoses of pervasive developmental disorders. *Am J Psychiatry* 169: 1056–1064.
16. Ozonoff S (2012) Editorial perspective: autism spectrum disorders in DSM-5—an historical perspective and the need for change. *J Child Psychol Psychiatry* 53: 1092–1094.
17. Mandy W, Charman T, Gilmour J, Skuse D (2011) Toward specifying pervasive developmental disorder-not otherwise specified. *Autism Res* 4: 121–131.
18. Greaves-Lord K, Eussen ML, Verhulst FC, Minderaa RB, Mandy W, et al. (2012) Empirically based phenotypic profiles of children with pervasive developmental disorders: interpretation in the light of the DSM-5. *J Autism Dev Disord*. Epub ahead of print 8 Dec 2012.
19. Geschwind DH, Levitt P (2007) Autism spectrum disorders: developmental disconnection syndromes. *Curr Opin Neurobiol* 17: 103–111.
20. Wing L (1975/1996) *The autistic spectrum: a guide for parents and professionals*. London: Constable & Robinson Ltd.
21. Allison C, Baron-Cohen S, Wheelwright S, Charman T, Richler J, et al. (2008) The Q-CHAT (Quantitative Checklist for Autism in Toddlers): a normally distributed quantitative measure of autistic traits at 18–24 months of age: preliminary report. *J Autism Dev Disord* 38: 1414–1425.
22. Williams JG, Allison C, Scott FJ, Bolton PF, Baron-Cohen S, et al. (2008) The Childhood Autism Spectrum Test (CAST): sex differences. *J Autism Dev Disord* 38: 1731–1739.
23. Posserud MB, Lundervold AJ, Gillberg C (2006) Autistic features in a total population of 7–9-year-old children assessed by the ASSQ (Autism Spectrum Screening Questionnaire). *J Child Psychol Psychiatry* 47: 167–175.
24. Robinson EB, Koenen KC, McCormick MC, Munir K, Hallett V, et al. (2011) Evidence that autistic traits show the same etiology in the general population and at the quantitative extremes (5%, 2.5%, and 1%). *Arch Gen Psychiatry* 68: 1113–1121.
25. Lundstrom S, Chang Z, Rastam M, Gillberg C, Larsson H, et al. (2012) Autism spectrum disorders and autistic like traits: similar etiology in the extreme end and the normal variation. *Arch Gen Psychiatry* 69: 46–52.
26. Constantino JN (2011) The quantitative nature of autistic social impairment. *Pediatr Res* 69: 55R–62R.
27. Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E (2001) The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. *J Autism Dev Disord* 31: 5–17.
28. Sucksmith E, Roth I, Hoekstra RA (2011) Autistic traits below the clinical threshold: re-examining the broader autism phenotype in the 21st century. *Neuropsychol Rev* 21: 360–389.
29. Wheelwright S, Auyeung B, Allison C, Baron-Cohen S (2010) Defining the broader, medium and narrow autism phenotype among parents using the Autism Spectrum Quotient (AQ). *Mol Autism* 1: 10.
30. Chakrabarti B, Dudbridge F, Kent L, Wheelwright S, Hill-Cawthorne G, et al. (2009) Genes related to sex steroids, neural growth, and social-emotional behavior are associated with autistic traits, empathy, and Asperger syndrome. *Autism Res* 2: 157–177.
31. Waterhouse L (2013) Rethinking autism: variation and complexity. London: Academic Press.
32. Happe F (2011) Criteria, categories, and continua: autism and related disorders in DSM-5. *J Am Acad Child Adolesc Psychiatry* 50: 540–542.
33. Moran M (2013) DSM-5 provides new take on neurodevelopmental disorders. *Psychiatr News* 48: 6–23.
34. Stefanatos GA (2008) Regression in autistic spectrum disorders. *Neuropsychol Rev* 18: 305–319.
35. Fountain C, Winter AS, Bearman PS (2012) Six developmental trajectories characterize children with autism. *Pediatrics* 129: e1112–1120.
36. Gotham K, Pickles A, Lord C (2012) Trajectories of autism severity in children using standardized ADOS scores. *Pediatrics* 130: e1278–1284.
37. Lai M-C, Lombardo MV, Pasco G, Ruigrok ANV, Wheelwright SJ, et al. (2011) A behavioral comparison of male and female adults with high functioning autism spectrum conditions. *PLoS ONE* 6: e20835. doi:10.1371/journal.pone.0020835
38. Lai M-C, Lombardo MV, Ruigrok ANV, Chakrabarti B, Wheelwright SJ, et al. (2012) Cognition in males and females with autism: similarities and differences. *PLoS ONE* 7: e47198. doi:10.1371/journal.pone.0047198
39. Gilman SR, Iossifov I, Levy D, Ronemus M, Wigler M, et al. (2011) Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. *Neuron* 70: 898–907.
40. Szatmari P, Liu XQ, Goldberg J, Zwaigenbaum L, Paterson AD, et al. (2012) Sex differences in repetitive stereotyped behaviors in autism: implications for genetic liability. *Am J Med Genet B Neuropsychiatr Genet* 159B: 5–12.
41. Schwarz E, Guest PC, Rahmoune H, Wang L, Levin Y, et al. (2011) Sex-specific serum biomarker patterns in adults with Asperger's syndrome. *Mol Psychiatry* 16: 1213–1220.
42. Beacher FD, Minati L, Baron-Cohen S, Lombardo MV, Lai M-C, et al. (2012) Autism attenuates sex differences in brain structure: a combined voxel-based morphometry and diffusion tensor imaging study. *AJNR Am J Neuroradiol* 33: 83–89.
43. Nordahl CW, Lange N, Li DD, Barnett LA, Lee A, et al. (2011) Brain enlargement is associated with regression in preschool-age boys with autism spectrum disorders. *Proc Natl Acad Sci U S A* 108: 20195–20200.
44. Baron-Cohen S, Lombardo MV, Auyeung B, Ashwin E, Chakrabarti B, et al. (2011) Why are autism spectrum conditions more prevalent in males? *PLoS Biol* 9: e1001081. doi:10.1371/journal.pbio.1001081
45. Legato MJ, editor (2010) *Principles of gender-specific medicine*. 2nd edition. London: Academic Press.
46. Werling DM, Geschwind DH (2013) Sex differences in autism spectrum disorders. *Curr Opin Neurol* (26)2: 146–153.
47. Dworzynski K, Ronald A, Bolton P, Happe F (2012) How different are girls and boys above and below the diagnostic threshold for autism spectrum disorders? *J Am Acad Child Adolesc Psychiatry* 51: 788–797.
48. Gillberg C (1991) Clinical and neurobiological aspects of Asperger's syndrome in six families studied. In: Frith U, editor. *Autism and Asperger's Syndrome*. Cambridge (United Kingdom): Cambridge University Press. pp. 122–146.
49. Wing L (1997) The autistic spectrum. *Lancet* 350: 1761–1766.
50. Baron-Cohen S (2009 November 9) The short life of a diagnosis. *The New York Times*: A35.
51. Klin A (2011) Asperger's syndrome: from Asperger to modern day. In: Amaral DG, Dawson G, Geschwind DH, editors. *Autism spectrum disorders*. New York: Oxford University Press. pp. 44–59.

52. Witwer AN, Lecavalier L (2008) Examining the validity of autism spectrum disorder subtypes. *J Autism Dev Disord* 38: 1611–1624.
53. Rinehart NJ, Bradshaw JL, Brereton AV, Tonge BJ (2002) A clinical and neurobehavioural review of high-functioning autism and Asperger's disorder. *Aust N Z J Psychiatry* 36: 762–770.
54. Frith U (2012) Why we need cognitive explanations of autism. *Q J Exp Psychol (Hove)* 65: 2073–2092.
55. Billstedt E, Gillberg C, Gillberg C (2005) Autism after adolescence: population-based 13- to 22-year follow-up study of 120 individuals with autism diagnosed in childhood. *J Autism Dev Disord* 35: 351–360.
56. Howlin P, Goode S, Hutton J, Rutter M (2004) Adult outcome for children with autism. *J Child Psychol Psychiatry* 45: 212–229.
57. Devlin B, Scherer SW (2012) Genetic architecture in autism spectrum disorder. *Curr Opin Genet Dev* 22: 229–237.
58. Heil KM, Schaaf CP (2013) The genetics of autism spectrum disorders—a guide for clinicians. *Curr Psychiatry Rep* 15: 334.
59. Moss J, Howlin P (2009) Autism spectrum disorders in genetic syndromes: implications for diagnosis, intervention and understanding the wider autism spectrum disorder population. *J Intellect Disabil Res* 53: 852–873.
60. Caglayan AO (2010) Genetic causes of syndromic and non-syndromic autism. *Dev Med Child Neurol* 52: 130–138.
61. Lintas C, Persico AM (2009) Autistic phenotypes and genetic testing: state-of-the-art for the clinical geneticist. *J Med Genet* 46: 1–8.
62. Geschwind DH (2011) Autism genetics and genomics: a brief overview and synthesis. In: Amaral DG, Dawson G, Geschwind DH, editors. *Autism spectrum disorders*. New York: Oxford University Press. pp. 812–824.
63. Ronald A, Hoekstra RA (2011) Autism spectrum disorders and autistic traits: a decade of new twin studies. *Am J Med Genet B Neuropsychiatr Genet* 156B: 255–274.
64. Corrales MA, Herbert M (2011) Autism and environmental genomics: synergistic systems approaches to autism complexity. In: Amaral DG, Dawson G, Geschwind DH, editors. *Autism spectrum disorders*. New York: Oxford University Press. pp. 875–892.
65. Rutter M, Kreppner J, Croft C, Murin M, Colvert E, et al. (2007) Early adolescent outcomes of institutionally deprived and non-deprived adoptees. III. quasi-autism. *J Child Psychol Psychiatry* 48: 1200–1207.
66. Rodier PM (2011) Environmental exposures that increase the risk of autism spectrum disorders. In: Amaral DG, Dawson G, Geschwind DH, editors. *Autism spectrum disorders*. New York: Oxford University Press. pp. 863–874.
67. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, et al. (2010) Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. *Am J Psychiatry* 167: 748–751.
68. Kapur S, Phillips AG, Insel TR (2012) Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? *Mol Psychiatry* 17: 1174–1179.